Entellus Medical, Inc. (NASDAQ:ENTL) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research note issued to investors on Monday. The firm currently has a $23.00 price target on the medical technology company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 18.07% from the company’s current price.
According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
ENTL has been the topic of a number of other research reports. BidaskClub upgraded Entellus Medical from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 14th. Piper Jaffray Companies reiterated a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $22.00.
Shares of Entellus Medical (NASDAQ ENTL) opened at 19.48 on Monday. Entellus Medical has a 52 week low of $12.31 and a 52 week high of $21.13. The company’s market cap is $494.23 million. The company’s 50-day moving average price is $18.18 and its 200 day moving average price is $18.18.
Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The business had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.27) EPS. Equities research analysts anticipate that Entellus Medical will post ($1.61) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Upgrades Entellus Medical, Inc. (ENTL) to Buy” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/10/11/zacks-investment-research-upgrades-entellus-medical-inc-entl-to-buy.html.
In other Entellus Medical news, VP Stephen R. Paidosh sold 25,000 shares of the stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $17.54, for a total transaction of $438,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Timothy B. Petrick sold 2,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $20.01, for a total value of $40,020.00. The disclosure for this sale can be found here. Insiders have sold 79,000 shares of company stock valued at $1,497,142 in the last three months. Insiders own 7.70% of the company’s stock.
Several institutional investors have recently made changes to their positions in the business. Frontier Capital Management Co. LLC raised its holdings in shares of Entellus Medical by 85.0% during the second quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock valued at $14,347,000 after acquiring an additional 397,953 shares during the last quarter. First Light Asset Management LLC raised its holdings in shares of Entellus Medical by 25.7% during the second quarter. First Light Asset Management LLC now owns 512,416 shares of the medical technology company’s stock valued at $8,486,000 after acquiring an additional 104,919 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Entellus Medical by 14.2% during the second quarter. Vanguard Group Inc. now owns 485,294 shares of the medical technology company’s stock valued at $8,036,000 after acquiring an additional 60,471 shares during the last quarter. Archon Capital Management LLC increased its holdings in shares of Entellus Medical by 34.3% in the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock valued at $7,929,000 after purchasing an additional 122,171 shares during the last quarter. Finally, Kingdon Capital Management L.L.C. increased its holdings in shares of Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock valued at $6,215,000 after purchasing an additional 199,615 shares during the last quarter. 70.27% of the stock is owned by institutional investors and hedge funds.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.